Investigational Drug Details
| Drug ID: | D193 |
| Drug Name: | Thioridazine |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00679 |
| DrugBank Description: | A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to it's association with cardiac arrythmias. |
| PubChem ID: | 5452 |
| CasNo: | 50-52-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | CSC1=CC2=C(SC3=CC=CC=C3N2CCC2CCCCN2C)C=C1 |
| Structure: |
|
| InChiKey: | KLBQZWRITKRQQV-UHFFFAOYSA-N |
| Molecular Weight: | 370.575 |
| DrugBank Targets: | Dopamine D2 receptor; Dopamine D1 receptor; Alpha-1A adrenergic receptor; Alpha-1B adrenergic receptor; 5-hydroxytryptamine receptor 2A; Potassium voltage-gated channel subfamily H member 2 |
| DrugBank MoA: | Thioridazine blocks postsynaptic mesolimbic dopaminergic D1 and D2 receptors in the brain; blocks alpha-adrenergic effect, depresses the release of hypothalamic and hypophyseal hormones and is believed to depress the reticular activating system thus affecting basal metabolism, body temperature, wakefulness, vasomotor tone, and emesis. |
| DrugBank Pharmacology: | Thioridazine is a trifluoro-methyl phenothiazine derivative intended for the management of schizophrenia and other psychotic disorders. Thioridazine has not been shown effective in the management of behaviorial complications in patients with mental retardation. |
| DrugBank Indication: | For the treatment of schizophrenia and generalized anxiety disorder. |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
